Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney drug combo study halted early

NCT ID NCT04743739

First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 23 times

Summary

This study looked at whether adding cyclosporine to rituximab works better than rituximab alone for treating a kidney condition called idiopathic membranous nephropathy. The trial planned to enroll many participants but was stopped early after only 12 people joined. The goal was to see if the combination could reduce protein in urine and improve blood protein levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing Luhe Hospital, Capital Medical University

    Beijing, Beijing Municipality, 101149, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100730, China

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100037, China

  • Nanyang Nanshi Hospital, Henan University

    Nanyang, Henan, 473065, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, 830054, China

  • The Seventh Affiliated Hospital, Sun Yat-sen University

    Shenzhen, Shenzhen, China

Conditions

Explore the condition pages connected to this study.